Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the debt to assets ratio high or low?
The debt to assets ratio of 24.71% is 12% below its 5-year average of 27.92%, around the middle of its 5-year range (1.06%–77.85%).
As of the fiscal period ended Tuesday, June 30, 2026. 56.06% below its 12-month average of 56.22%.
Reported quarterly debt to assets ratio; no daily interpolation. Q2 FY2026 (2026-06-30): 24.71%.
DEBT TO ASSETS RATIO
24.71%
DEBT TO ASSETS RATIO AVG TTM
56.22%
DEBT TO ASSETS RATIO AVG 3Y
34.78%
DEBT TO ASSETS RATIO AVG 5Y
27.92%
DEBT TO ASSETS RATIO AVG 10Y
N/A
DEBT TO ASSETS RATIO AVG 15Y
N/A
DEBT TO ASSETS RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
-56.06%
CURRENT VS 3Y AVG
-28.96%
CURRENT VS 5Y AVG
-11.52%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
0.10%
median of 580 covered companies
CURRENT VS SECTOR MEDIAN
+24605.80%
vs the sector median at left
Liquidia Corporation
Market Cap
$2.40B
Debt to Assets Ratio
24.71%
TTM Avg
56.22%
3Y Avg
34.78%
5Y Avg
27.92%
Market Cap
$2.42B
Debt to Assets Ratio
0.05%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$2.39B
Debt to Assets Ratio
0.00%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$2.47B
Debt to Assets Ratio
0.13%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$2.32B
Debt to Assets Ratio
0.30%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$2.30B
Debt to Assets Ratio
0.29%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$2.56B
Debt to Assets Ratio
0.18%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$2.28B
Debt to Assets Ratio
0.11%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | DEBT TO ASSETS RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Liquidia Corporation (LQDA) | $2.40B | 24.71% | 56.22% | 34.78% | 27.92% |
| Disc Medicine, Inc. (IRON)vs › | $2.42B | 0.08% | N/A | N/A | N/A |
| Recursion Pharmaceuticals, Inc. (RXRX)vs › | $2.42B | 0.05% | N/A | N/A | N/A |
| Clover Health Investments, Corp. (CLOV)vs › | $2.39B | 0.00% | N/A | N/A | N/A |
| Alamar Biosciences, Inc. (ALMR)vs › | $2.47B | 0.13% | N/A | N/A | N/A |
| ADMA Biologics, Inc. (ADMA)vs › | $2.32B | 0.30% | N/A | N/A | N/A |
| Maravai LifeSciences Holdings, Inc. (MRVI)vs › | $2.30B | 0.29% | N/A | N/A | N/A |
| Beam Therapeutics Inc. (BEAM)vs › | $2.56B | 0.18% | N/A | N/A | N/A |
| Harmony Biosciences Holdings, Inc. (HRMY)vs › | $2.28B | 0.11% | N/A | N/A | N/A |
| NewAmsterdam Pharma Company N.V. (NAMS)vs › | $2.59B | 0.00% | N/A | N/A | N/A |
Debt/Assets
24.7%
Debt/Equity
0.66
Current Ratio
2.31
Interest Coverage
-2.1x
Formula: Debt/Assets = Total Debt / Total Assets × 100
Debt/Assets vs Debt/Equity:
Industry context matters: Capital-intensive industries (utilities, real estate) typically have higher Debt/Assets ratios than tech companies.
Debt/Assets ratio shows what percentage of a company's assets are financed by debt. Compare the current value with the historical chart and peer group to understand leverage over time.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | DEBT TO ASSETS RATIO |
|---|---|
| 2026-06-30 | 24.71% |
| 2026-03-31 | 46.03% |
| 2025-12-31 | 60.36% |
| 2025-09-30 | 72.17% |
| 2025-06-30 | 77.85% |
| 2025-03-31 | 64.93% |
| 2024-12-31 | 53.14% |
| 2024-09-30 | 1.06% |
| 2024-06-30 | 1.66% |
| 2024-03-31 | 1.64% |
| 2023-12-31 | 41.86% |
| 2023-09-30 | 3.38% |
| 2023-06-30 | 3.31% |
| 2023-03-31 | 3.31% |
| 2022-12-31 | 18.93% |
| 2022-09-30 | 18.56% |
| 2022-06-30 | 17.79% |
| 2022-03-31 | 26.60% |
| 2021-12-31 | 17.16% |
| 2021-09-30 | 16.22% |
| 2021-06-30 | 15.75% |
| 2021-03-31 | 18.77% |
| 2020-12-31 | 17.22% |
| 2020-09-30 | 20.78% |
| 2020-06-30 | 58.62% |
| 2020-03-31 | 42.79% |
| 2019-12-31 | 35.47% |
| 2019-09-30 | 46.62% |
| 2019-06-30 | 38.14% |
| 2019-03-31 | 26.65% |
| 2018-12-31 | 25.85% |
| 2018-09-30 | 20.93% |
| 2018-06-30 | 64.87% |
| 2018-03-31 | 45.45% |
| 2017-12-31 | 149.19% |
